Winners And Losers in CLL at ASCO '13 - a marketing strategy consultant's perspective

[AussieNeil]

Pieter Droppert writes the Biotech Strategy Blog "The Street" and is a marketing strategy consultant with a focus on oncology/hematology new product development.

In his blog "Winners And Losers in CLL at ASCO '13", he writes:

"New products in development for chronic lymphocytic leukemia (CLL), an incurable B-cell cancer, will transform the treatment of this disease over the next few years.

CLL offers a big market opportunity as more than 150,000 people in the U.S. and Europe have the disease, and about a third of these require first or second-line therapy."

He covers in particular how the new drugs by Gilead Sciences (idelalisib), Roche (Obinutuzumab - GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (Ibrutinib) fared in their ASCO presentations and which companies with CLL drug development in the pipeline were absent from ASCO.

More:

thestreet.com/story/1194443...

Neil